United Capital Financial Advisors LLC Buys Shares of 19,104 DexCom, Inc. $DXCM

United Capital Financial Advisors LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, HoldingsChannel reports. The fund bought 19,104 shares of the medical device company’s stock, valued at approximately $1,287,000.

Other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of DexCom during the 4th quarter valued at $483,356,000. AQR Capital Management LLC increased its holdings in DexCom by 597.8% in the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock worth $205,932,000 after purchasing an additional 2,658,158 shares in the last quarter. Legal & General Group Plc bought a new position in DexCom in the second quarter valued at about $173,237,000. Deutsche Bank AG bought a new position in DexCom in the second quarter valued at about $164,035,000. Finally, Employees Provident Fund Board acquired a new stake in shares of DexCom during the fourth quarter valued at about $145,352,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Kevin R. Sayer sold 26,756 shares of the business’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider owned 328,970 shares in the company, valued at $25,106,990.40. The trade was a 7.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 75,600 shares of company stock worth $5,673,342. Company insiders own 0.28% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DXCM. Benchmark upped their price objective on DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Canaccord Genuity Group set a $90.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Monday, August 3rd. Royal Bank Of Canada upped their price target on shares of DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. raised their price target on shares of DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a research note on Friday, July 31st. Finally, Wall Street Zen lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $88.71.

DexCom Stock Performance

DXCM stock opened at $90.82 on Friday. The firm has a market cap of $34.27 billion, a PE ratio of 35.90, a price-to-earnings-growth ratio of 1.53 and a beta of 1.41. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock has a 50-day moving average price of $79.21 and a 200-day moving average price of $71.60. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same quarter in the prior year, the company earned $0.48 EPS. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. As a group, equities research analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.